Prognostic Role of Macular Neovascular Membrane Subtype in Pneumatic Displacement of Macular Hemorrhages
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50+
SponsorMarco Mazzola
About this trial
This study investigates the prognostic value of macular neovascularization (MNV) subtypes in patients treated with pneumatic displacement for submacular hemorrhage. The researchers will compare anatomical and functional outcomes (visual acuity) between PCV, RAP, and other MNV forms within a Caucasian cohort to identify subtype-specific predictors of recovery.
Eligibility criteria
Qualifiers
Patients undergoing pneumatic displacement (PD) for submacular hemorrhage (SMH), secondary to macular neovascularization (MNV)
Age 50 years or older at the time of SMH diagnosis
Caucasian ethnicity
SMH involving the central or internal ring of the Early Treatment Diabetic Retinopathy Study (ETDRS) grid (within a 3 mm circumference centered on the fovea)
Disqualifiers
SMH estimated to be present for more than 15 days at the time of diagnosis
SMH secondary to conditions other than MNV
Presence of proliferative diabetic retinopathy in the study eye
Aphakia in the study eye
Trial design
Treatments tested in this trial
- Not listed
Trial groups
60 Participants
are grouped into 3 trial groupsSponsors and collaborators
Marco Mazzola
Lead sponsor
Azienda Sanitaria Universitaria Integrata del Trentino
Sponsor institution
Source ClinicalTrials.gov